![share_log](https://usnewsfile.moomoo.com/20230625000012291e57d0213b0.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
牛牛AI助理已提取核心訊息
On June 11, 2024, 60 Degrees Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug tafenoquine for the treatment of acute babesiosis. This designation provides the company with benefits such as market exclusivity, tax credits, and exemption from certain FDA fees. The company has also partnered with Tufts Medical Center to conduct the first clinical trial evaluating tafenoquine's efficacy and safety in treating human babesiosis. Babesiosis is a disease transmitted by ticks, which can be severe in certain populations. The trial is set to begin recruitment on June 13, 2024, and will involve at least 24 patients. Tafenoquine is already approved for malaria prophylaxis under the name ARAKODA®. The company, which specializes in developing treatments for infectious diseases, is headquartered in Washington D.C. and has a subsidiary in Australia.
On June 11, 2024, 60 Degrees Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug tafenoquine for the treatment of acute babesiosis. This designation provides the company with benefits such as market exclusivity, tax credits, and exemption from certain FDA fees. The company has also partnered with Tufts Medical Center to conduct the first clinical trial evaluating tafenoquine's efficacy and safety in treating human babesiosis. Babesiosis is a disease transmitted by ticks, which can be severe in certain populations. The trial is set to begin recruitment on June 13, 2024, and will involve at least 24 patients. Tafenoquine is already approved for malaria prophylaxis under the name ARAKODA®. The company, which specializes in developing treatments for infectious diseases, is headquartered in Washington D.C. and has a subsidiary in Australia.
2024年6月11日,60度醫藥公司宣佈,美國食品和藥物管理局(FDA)授予其開發中的藥品Tafenoquine治療急性住血質病的孤兒藥品稱號。該稱號爲公司提供了市場獨佔、稅收抵免和免除某些FDA費用等優惠。該公司還與塔夫茨醫學中心展開了合作,進行了第一項評估Tafenoquine在治療人類住血質病中療效及安全性的臨床試驗。住血質病是由蜱傳播的一種疾病,在特定人群中可能很嚴重。該試驗將於2024年6月13日開始招募至少24名患者。Tafenoquine已經以名稱ARAKODA®的形式獲得了瘧疾預防的批准。該公司專門從事感染性疾病的治療,總部位於華盛頓特區,在澳洲設有子公司。
2024年6月11日,60度醫藥公司宣佈,美國食品和藥物管理局(FDA)授予其開發中的藥品Tafenoquine治療急性住血質病的孤兒藥品稱號。該稱號爲公司提供了市場獨佔、稅收抵免和免除某些FDA費用等優惠。該公司還與塔夫茨醫學中心展開了合作,進行了第一項評估Tafenoquine在治療人類住血質病中療效及安全性的臨床試驗。住血質病是由蜱傳播的一種疾病,在特定人群中可能很嚴重。該試驗將於2024年6月13日開始招募至少24名患者。Tafenoquine已經以名稱ARAKODA®的形式獲得了瘧疾預防的批准。該公司專門從事感染性疾病的治療,總部位於華盛頓特區,在澳洲設有子公司。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了